Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., priced its public offering of about 7.6 million shares at $4.60 per share, a 6 percent discount to Thursday’s closing price. Read More
Ignyta Inc., of San Diego, said preliminary results were presented from the ongoing phase I dose escalation portion of a phase I/II trial of RXDX-101, Ignyta’s oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting. Read More
Teva Pharmaceutical Industries Ltd., of Jerusalem, said the European Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for Duoresp Spiromax (budesonide and formoterol fumarate dehydrate) inhalation powder for the treatment of patients with asthma and chronic obstructive pulmonary disease when a combination inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate. Read More
Janssen Research & Development LLC, of Raritan, N.J., part of Johnson & Johnson, started the CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) phase III, global, multicenter study of Invokana (canagliflozin). Read More
A team from the Swedish Karolinska Institutet has developed a strategy to preferentially target nondividing cells in nutrient-poor tumor regions by attacking their mitochondrial function. Classical chemotherapies target rapidly dividing cells, but not all tumor cells are dividing rapidly at any given time. Read More
Exelixis Inc., of South San Francisco, reported net revenues of $4.3 million for the fourth quarter and $31.3 million for the full year, including net product revenues of $4.3 million and $15 million, respectively, for the fourth quarter and full year sales of Cometriq (cabozantinib), which was launched in January 2013 for medullary thyroid cancer. Read More
Calling the top-line phase Ia/IIb data with the company’s antisense drug for spinal muscular atrophy (SMA) in children “achingly important” and the benefit in a subset “shocking,” Isis Pharmaceuticals Inc. CEO Stanley Crooke said intrathecal ISIS-SMNRx has proven safe so far, too. Read More
Last week we learned which 10 deals – five biopharma licensing and five M&A deals negotiated in 2013 – made the cut as candidates for the Breakthrough Alliance Awards. Read More
The ultra-rare disease creatine transporter deficiency (CTD) wreaks havoc on its patient population of young boys. The x-linked autism spectrum disorder prevents the transport of creatine – a nitrogenous organic acid that serves as fuel for the body’s cells – into the brain, causing patients to suffer seizures, speech delay, behavioral abnormalities and severe cognitive impairment. Read More
By applying modern science principles to evaluating traditional Chinese medicine, researchers have gained new insights into how acupuncture works. And just as importantly from a scientific perspective, they have been able to understand why, sometimes, it doesn’t. Read More
Endo Pharmaceuticals Inc., of Malvern, Pa., reached a resolution of criminal and civil claims with the federal and participating state authorities and the District of Columbia regarding a previously disclosed investigation concerning past U.S. sales, marketing and promotional practices related to its product Lidoderm (lidocaine patch 5 percent). Read More
